

Corp. Office : 1st to 4th Floor, SM House, 11, Sahakar Road, Vile Parle (East), Mumbai - 400 057.
Tel. : (91-22) 6726 1000 Fax : (91-22) 6726 1068 E-mail : info@guficbio.com, CIN No. L24100MH1984PLC033519

16/LG/SE/JAN/2020/GBSL

21st January, 2020

To
The Manager (CRD)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400 001

To
The Manager
National Stock Exchange Of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code : 509079

Symbol : GUFICBIO

Dear Sir,

Sub: Submission of Report on Reconciliation of Share Capital Audit for the quarter ended December 31, 2019.

With reference to above, we submit herewith Report on Reconciliation of Share Capital Audit for the quarter ended December 31, 2019 for reconciliation of share capital in electronic mode and physical mode, received from M/s. Gajanan D. Athavale, Practicing Company Secretary, Mumbai.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Gufic Biosciences Limited



Ami N. Shah
Company Secretary & Compliance Officer
Mem No. A39579



Encl: A/a



To,
The Board of Directors,
Gufic Biosciences Limited
Mumbai

Reconciliation of Share Capital Audit of M/s. Gufic Biosciences Limited

BSE Scrip Code: 509079

NSE Scrip Code: GUFICBIO

Company Identification Number: L24100MH1984PLC033519

Sir/Madam,

Based on reports/certificates of the Company appointed Registrars and Transfer Agents; M/s. Link Intime India Pvt. Ltd., which was further supported by the management's written representation dated 21 January 2020; in terms of Regulation 55A of the SEBI (Depositories and Participants) Regulations, 1996 read with the Circular D&CC/FITTC/CIR-16/2002 dated 31 December 2002 as amended by the Circular No. SEBI/MRD/ Policy/Cir-13/2004 dated March 3, 2004 and circular CIR/MRD/DP/30/2010 dated 06 September 2010, *presently in force and to the extent repealed by regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018*; I hereby report on the reconciliation of share capital of Gufic Biosciences Limited for the quarter ended 31 December 2019 as follows in a prescribed format:

Sr. No.	Particulars	
1.	For the quarter ended	31 December 2019
2.	ISIN	INE742B01025
3.	Face Value	Re.1/-
4.	Name of the Company	Gufic Biosciences Limited
5.	Registered Office Address	Shop 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai – 400 069
6.	Correspondence Address (Corporate Office)	S M house, 11 Sahakar Road, Vile Parle (East), Mumbai – 400057
7.	Telephone & Fax	Tele: 022 – 67261000 Fax: 022 – 67261067
8.	Email ID	mgr_legal@guficbio.com
9.	Names of the Stock Exchanges where the company's securities are listed	1. Bombay Stock Exchange Limited (BSE) 2. National Stock Exchange of India Limited (NSE)





10.	Issued Capital	Number of Equity Shares		issued capital %		
		77,830,000		100		
11.	Listed Capital (Exchange-wise) (as per company records)	77,830,000 (similar listing on both exchanges viz: BSE & NSE)		100		
12.	Held in dematerialised form in NSDL	7,26,73,466		93.37		
13.	Held in dematerialised form in CDSL	50,40,038		6.48		
14.	Physical	1,16,496		0.15		
15.	Total No. of Shares (12 + 13 + 14)	7,78,30,000		100.00		
16.	Reasons for difference if any, between (10 & 11), (10 & 15), (11 & 15)	--- N.A. ---				
17.	Certifying the details of changes in share capital during the quarter under consideration as per table below:					
	Particulars (Rights, Bonus, Preferential Issue, Amalgamation, Conversion, Capital Forfeiture, any other (to specify)	No. of shares	Applied / Not Applied for listing	Listed on Stock Exchanges (Specify Names)	Whether intimated to CDSL	Whether intimated to NSDL
----- N.A. -----						
18.	Register of Members is updated (Yes / No) If not, updated upto which date	Yes (as confirmed by RTA vide its letter dated 02 January 2020)				
19.	Reference of previous quarter with regards to excess dematerialised shares, if any.	N.A.				
20.	Has the company resolved the matter mentioned in point no.19 above in the current quarter? If not, reason why?	N.A.				
21.	Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending, beyond 21 days with the reasons for delay.					
	Total no. of demat requests	No. of requests	No. of shares	Reasons for delay		
	Confirmed after 21 days Pending for more than 21 days	As per reports of RTA, during the quarter no request for DEMAT, transfer, transmission, etc., were received, except the share transfer to IEPF by way of corporate action.				



[Handwritten signature]



01, Pushpak, Bhaskar Colony, Naupada, Thane (W), Maharashtra State – 400 602

E: gajanan@aathavale.com | U: www.aathavale.com | M: +91-9870567711

22.	Name, Telephone & Fax No. of the Compliance Officer of the Company	Ami Shah, Company Secretary & Compliance Officer Tel: 022 – 67261000 Fax: 022 – 67261067
23.	Name, Address, Tel. & Fax No., Regn. no. of the Auditor	Gajanan D. Athavale, Company Secretaries 01, Pushpak, Bhaskar Colony, Naupada, Thane (West), Maharashtra State – 400 602 Membership No. F-9177 CoP No. 10121
24.	Appointment of common agency for share registry work, if yes (name & address)	LINK INTIME INDIA PVT. LTD. C-101, 247 Park, L.B.S. Marg, Vikhroli (W), Mumbai - 400 083. Tel No.: (022) 4918 6270 Fax (022) 49186060 Email: rnt.helpdesk@linkintime.co.in or mumbai@linkintime.co.in
25.	Any other detail that the auditor may like to provide. (e.g. BIFR company, delisting from SE, company changed its name etc.)	N.A.

For Gajanan D. Athavale
Company Secretaries

Gajanan D. Athavale
Proprietor



Membership No. FCS-9177

Certificate of Practice: 10121

UDIN F009177B000080921

Place: Thane

Date: 21 January 2020